Join us in celebrating the launch of Project 1st STOP (Safe Treatment and Overdose Prevention)—JSAS HealthCare’s new Mobile Medication Unit designed to expand access to lifesaving treatment and community outreach.
Neptune, NJ — August 2025 — JSAS HealthCare, Inc. (JSASHC) is proud to announce it has been awarded funding through a competitive Request for Proposal (RFP) process by the New Jersey Department of Human Services, Division of Mental Health and Addiction Services (NJDMHAS) to establish a Mobile Medication Unit (MMU) for Opioid Use Disorder (OUD).
When it comes to the opioid crisis, collaboration makes all the difference. Join us at the Mobile Health Leadership Summit on August 13-14, 2025, where three industry leaders—including JSAS Healthcare’s Margaret B. Rizzo—will share how they’re driving real change in treatment and recovery. These voices are reshaping how care is delivered, meeting people where they are with compassion, innovation, and action.
In September 2024, JSAS HealthCare was awarded funding through a competitive Request for Proposal process by the New Jersey Department of Human Services, Division of Mental Health and Addiction Services (NJDMHAS) to establish a mobile medication unit (MMU) for Opioid Use Disorder (OUD). We expect Project 1st STOP (Safe Treatment and Overdose Prevention) to be fully operational by April 1, 2025. As supported by the data gathered during the RFP process, JSAS HealthCare (JSASHC’s) Project 1st STOP will target Northern
Maiysha Ware, NJATOD President, accepted the notable Nyswander/Dole “Marie” Award which is the highest accolade AATOD can bestow on someone in recognition for having made significant contributions in the field of opioid use disorder treatment.
Explore NJATOD’s latest advocacy efforts detailed in a comprehensive letter addressing the 42 CFR Part 8 Final Rule. This crucial document outlines NJATOD’s proposed recommendations and urgent requests to state regulators, aiming to align federal and state policies to enhance opioid treatment programs in New Jersey.
New Jersey is making significant strides in expanding access and eliminating transportation barriers to medication-assisted treatment for opioid use disorders. This is being achieved through the implementation of the New Jersey Department of Human Services, Division of Mental Health and Addiction Services’ (NJDMHAS) Medication Assisted Treatment Initiative (MATI) and Travel Reimbursement and Invoicing Program (TRIP).
The New Jersey Association for the Treatment of Opioid Dependence (NJATOD) expresses strong concerns over the Modernizing Opioid Treatment Access Act (MOTAA), advocating for alignment with recent SAMHSA regulations instead. Highlighting risks such as increased overdoses, NJATOD urges a reconsideration of the act, emphasizing the need for safe and regulated treatment expansion through proven methods like mobile services.
